Ophthalmology

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.

Nearly 19% of dementia cases were attributable to ≥1 vision impairment in a nationally representative sample of older US adults.

This August 2024 month in review highlights updates to the ophthalmic pipeline, metformin for geographic atrophy, and decreasing rates of postoperative endophthalmitis in the US.

Panretinal photocoagulation followed by anti-VEGF injections increases the likelihood of PPV, compared with anti-VEGF therapy first.

After an initial switch to faricimab, anatomical measures showed improvement while no functional improvement was identified in real-world data.

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Brolucizumab achieved non-inferiority in mean BCVA change to aflibercept in eyes with nAMD but demonstrated a higher incidence of IOI at 2 years.

A retrospective study in Japan identified 3 cases of non-infectious IOI associated with retinal vasculitis after aflibercept 8 mg treatment.

Nocturnal hypoxia may represent an additional modifiable risk factor for AMD, particularly its neovascular form.

Higher hemoglobin levels during early postnatal days may protect against the development of ROP in preterm infants.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

A deep-learning model displayed a strong performance in accurately identifying myopia, strabismus, and ptosis using smartphone images.

Ocugen will initiate expanded access to OCU400 gene therapy in adults with retinitis pigmentosa prior to BLA approval.

Postprocedure endophthalmitis substantially decreased between 2000 and 2002, with prompt vitrectomy used less frequently as first-line treatment.

Our July 2024 month in review in ophthalmology includes the latest updates to the ophthalmological pipeline and a trio of studies on the treatment landscape for retinal diseases.

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

A first-time comparison in US patients displays the protective association of DOACs over warfarin use on RVO and intraocular bleeding risk.

A teleretinal screening program improved the awareness of sickle cell retinopathy and motivated patients to visit an eye care provider.

Older patient age was linked to suboptimal anti-VEGF response for diabetic macular edema in DRCR clinical trials.

Geographic atrophy in eyes with dry AMD and macular atrophy in fellow eyes with neovascular AMD demonstrate similar growth rates.

A recap of the 5 most popular topics related to gene therapy in ophthalmology coming from the 42nd American Society of Retina Specialists meeting.

Hesitancy with anti-VEGF biosimilars was identified in a survey among both ophthalmologists and patients with nAMD in Canada.

Across 40 clinical scenarios, ChatGPT did not provide a comprehensive response in 50% of clinical questions with nearly 30% hallucinated sources.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

A database analysis linked semaglutide use to notable reductions in the rates of diabetic macular edema and vitreous hemorrhage in diabetic retinopathy.

The FDA accepted Genentech’s supplemental BLA for Susvimo, based on the one-year results from the Phase III Pagoda and Pavilion studies.

New research presented at ASRS 2024 links maternal asthma to a higher risk of advanced retinopathy of prematurity.